Figure 3.

Forest plot showing that the risk reduction of kidney outcomes with empagliflozin versus placebo is consistent across KDIGO risk categories. Cox regression analysis in patients treated with one or more doses of study drug. *Sixty-eight patients were excluded as the subgroup variable was missing. ^†Accompanied by eGFR≤45 ml/min per 1.73 m². Macroalbuminuria: urine albumin-creatinine ratio >300 mg/g.